CXCR

CXC chemokine receptors; C-X-C motif chemokine receptors

CXCR

Related Products

CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells. The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.

CXCR Isoform Specific Products:

CXCR Isoform Comparison

CXCR Related Products (225)
Recombinant Proteins (142)
Antibodies (9)
Related Compound Screening Libraries (1)
CXCR Isoform Comparison

By Effects:	Control (1) Inhibitors (56) Agonists (17) Antagonists (97) Activators (2) Modulators (9)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-10046

Plerixafor	Antagonist	99.90%
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM.

HY-16711

SB225002	Antagonist	99.87%
SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits ¹²⁵I-IL-8 binding to CXCR2 with an IC₅₀ of 22 nM.

HY-15319

AMG 487	Inhibitor	99.80%
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC₅₀s of 8.0 and 8.2 nM, respectively.

HY-15251

Reparixin	Inhibitor	99.99%
Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC₅₀s of 1 and 100 nM, respectively.

HY-100806

Kynurenic acid		99.21%
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.

HY-P4111A

Peptide R TFA	Antagonist	98.34%
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research.

HY-10011A

(S)-SCH 563705	Antagonist	99.94%
(S)-SCH 563705 is a S-enantiomer of SCH 563705. SCH 563705 (compound 16) is a potent and orally available CXCR2 and CXCR1 antagonist, with IC₅₀s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively.

HY-10011B

(Rac)-SCH 563705	Antagonist	99.78%
(Rac)-SCH 563705 is a racemic mixture of SCH 563705 (HY-10011). SCH 563705 (compound 16) is a potent and orally active CXCR2 and CXCR1 antagonist with IC₅₀ values of 1.3 nM and 7.3 nM and K_i values of 1 nM and 3 nM, respectively.

HY-50912

Plerixafor octahydrochloride	Antagonist	99.09%
Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM.

HY-10198

Navarixin	Antagonist	98.90%
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with K_d values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.

HY-13848

AZD8797		99.54%
AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with K_is of 3.9 and 2800 nM, respectively.

HY-19855

AZD-5069	Antagonist	99.91%
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

HY-13406

TAK-779	Antagonist	99.73%
TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a K_i of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC₅₀ and EC₉₀ of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.

HY-P0171

Motixafortide	Antagonist	99.88%
Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC₅₀ vakue of ～1 nM.

HY-142617

ACT-1004-1239	Antagonist	99.80%
ACT-1004-1239 is a potent, selective, orally active CXCR7 antagonist with an IC₅₀ value of 3.2 nM.

HY-N0011

Baohuoside I	Inhibitor	99.96%
Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.

HY-122197

ML339	Antagonist	99.88%
ML339 is a selective CXCR6 antagonist with an IC₅₀ of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC₅₀ of 0.3 μM and 1.4 μM, respectively. ML339 shows weaker activity against the recruitment of β-arrestin in mouse CXCR6 receptors, with an IC₅₀ of 18 μM. ML339 has no inhibitory effect on CXCR5，CXCR4，CXCR6 and apelin receptor (APJ), with IC₅₀ >79 μM. ML339 has the potential to promote the development of prostate cancer research.

HY-50101A

Mavorixafor trihydrochloride	Antagonist	99.75%
Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively.Mavorixafor trihydrochloride can be used for the study of WHIM syndrome.

HY-119339

SX-682	Inhibitor	99.67%
SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.

HY-111793A

NUCC-390 dihydrochloride	Agonist	98.19%
NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046). NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo.

Chemokine Compound Library

Compound library containing a variety of Chemokine or Chemokine receptor inhibitors and activators.

187compounds HY-L132

Plerixafor					¹²⁵I-CXCL12-CXCR4, IC₅₀: 44 nM			99.90%
SB225002			¹²⁵I-IL-8-CXCR2, IC₅₀: 22 nM (in CHO cell membrane)					99.87%
AMG 487				¹²⁵I-IP10-CXCR3, IC₅₀: 8 nM ¹²⁵I-ITAC-CXCR3, IC₅₀: 8.2 nM				99.80%
Reparixin		CXCR1^wt, IC₅₀: 5.6 nM (in L1.2 cells) CXCR1^Ile43Val, IC₅₀: 80 nM (in L1.2 cells) CXCR1, IC₅₀: 1 nM (in cells)	CXCR2, IC₅₀: ∼100 nM (in cells)					99.99%
Peptide R TFA					CXCR4			98.34%
Plerixafor octahydrochloride					¹²⁵I-CXCL12-CXCR4, IC₅₀: 44 nM			99.09%
Navarixin		Cynomolgus CXCR1, Kd: 41 nM ¹²⁵I-CXCL8-CXCR1, IC₅₀: 43 nM	Mouse CXCR2, Kd: 0.2 nM Rat CXCR2, Kd: 0.2 nM Cynomolgus CXCR2, Kd: 0.08 nM ¹²⁵I-CXCL8-CXCR2, IC₅₀: 0.97 nM					98.90%
AZD8797			¹²⁵I-IL-8-CXCR2, Ki: 2800 nM (in HEK293S cells)					99.54%
AZD-5069			¹²⁵I-IL-8-CXCR2					99.91%
TAK-779				mCXCR3, IC₅₀: 369 nM (in PBMCs)				99.73%
Motixafortide					CXCR4, IC₅₀: ~1 nM			99.88%
ACT-1004-1239						CXCR7		99.80%
Baohuoside I					CXCR4			99.96%
ML339							CXCR6, IC₅₀: 140 nM	99.88%
Mavorixafor trihydrochloride					¹²⁵I-SDF-CXCR4, IC₅₀: 13 nM			99.75%
SX-682		CXCR1	CXCR2					99.67%
NUCC-390 dihydrochloride					CXCR4			98.19%
IT1t dihydrochloride					CXCL12/CXCR4, IC₅₀: 2.1 nM			99.77%
SCH 546738				Human CXCR3, Ki: 0.4 nM				98.71%
LY2510924					¹²⁵I-SDF-1α-CXCR4, IC₅₀: 79.7 pM ¹²⁵I-SDF-1α-CXCR4, Ki: 49.5 pM			99.73%
CXCR7 antagonist-1						CXCR7		99.85%
SB-265610			CXCR2					≥99.0%
VUF11207 fumarate						CXCR7, pKi: 8.1		98.50%
Danirixin			CXCL8-CXCR2, IC₅₀: 12.5 nM					98.88%
Reparixin L-lysine salt		CXCR1^wt, IC₅₀: 5.6 nM (in L1.2 cells) CXCR1^Ile43Val, IC₅₀: 80 nM (in L1.2 cells) CXCR1, IC₅₀: 1 nM (in cells)	CXCR2, IC₅₀: ∼100 nM (in cells)					99.66%
NBI-74330				[¹²⁵I]CXCL10-CXCR3, Ki: 1.5 nM (in CXCR3-CHO cell membranes) [¹²⁵I]CXCL11-CXCR3, Ki: 3.2 nM (in CXCR3-CHO cell membranes)				98.57%
ACT-777991				CXCR3				99.86%
Ulocuplumab					CXCR4			99.90%
Nicotinamide N-oxide			CXCR2					99.85%
TC14012					CXCR4, IC₅₀: 19.3 nM (antagonist site)	CXCR7, EC₅₀: 350 nM (agonist site)		98.92%
PS372424 hydrochloride				Human CXCR3				≥98.0%
Balixafortide TFA					CXCR4, IC₅₀: <10 nM			99.78%
WZ811					CXCR4, EC₅₀: 0.3 nM			99.80%
Elubrixin tosylate			CXCR2					99.78%
Ladarixin sodium		CXCR1	CXCR2					99.84%
CTCE-0214					SDF-1α-CXCR4			98.94%
CXCR2 antagonist 8			CXCR2					99.24%
SX-517		CXCR1	CXCR2					99.88%
Burixafor hydrobromide					CXCR4			≥98.0%
AMD 3465 hexahydrobromide					12G5 mAb-CXCR4, IC₅₀: 0.75 nM (in SupT1 cells) CXCL12^AF647-CXCR4, IC₅₀: 18 nM (in SupT1 cells)			≥98.0%
MSX-122					CXCR4/CXCL12, IC₅₀: ~10 nM			98.92%
SCH 563705		CXCR1, Ki: 3 nM CXCR1, IC₅₀: 7.3 nM	CXCR2, Ki: 1 nM CXCR2, IC₅₀: 1.3 nM Mouse CXCR2, IC₅₀: 5.2 nM					99.86%
CXCR2-IN-1			CXCR2, pIC₅₀: 9.3					99.54%
CXCR2-IN-2		CXCR1, IC₅₀: 3.8 μM	CXCR2, IC₅₀: 5.2 nM					99.52%
FC131 TFA					¹²⁵I-SDF-1-CXCR4, IC₅₀: 4.5 nM			99.89%
CTCE-9908					CXCR4			99.47%
CXCR7 antagonist-1 hydrochloride						CXCR7		99.41%
CXCR7 modulator 2						CXCR7, Ki: 13 nM		98.71%
ALX 40-4C Trifluoroacetate					SDF-1-CXCR4, Ki: 1 μM
AMD 3465					12G5 mAb-CXCR4, IC₅₀: 0.75 nM (in SupT1 cells) CXCL12^AF647-CXCR4, IC₅₀: 18 nM (in SupT1 cells)			99.59%
USL311					CXCR4			99.97%
LIT-927					CXCL12/CXCR4, Ki: 267 nM			99.86%
UNBS5162	CXCL							98.10%
AZD8309			CXCR2, IC₅₀: 4 nM					99.98%
ACT-660602				CXCR3, IC₅₀: 204 nM				99.86%
CXCR7 modulator 1						CXCR7, Ki: 9 nM		99.50%
AMG 487 (S-enantiomer)				CXCR3				99.94%
MSX-127					CXCR4			99.68%
SRT3190			CXCR2					99.77%
EPI-X4					CXCR4, IC₅₀: 8.6 μM			99.21%
NUCC-390					CXCR4			98.40%
Mavorixafor hydrochloride					¹²⁵I-CXCL12-CXCR4, IC₅₀: 13 nM			99.10%
Elubrixin			CXCR2
IT1t					CXCL12/CXCR4, IC₅₀: 2.1 nM
Peptide R					CXCR4
CXCR3 antagonist 1				CXCR3, IC₅₀: 0.06 μM				98.40%
ALX 40-4C					SDF-1-CXCR4, Ki: 1 μM
PS372424				Human CXCR3
Mavorixafor					¹²⁵I-SDF-CXCR4, IC₅₀: 13 nM
MSX-130					CXCR4			98.00%
KRH-3955 hydrochloride					SDF-1α-CXCR4, IC₅₀: 0.61 nM
FC131					¹²⁵I-SDF-CXCR4, IC₅₀: 4.5 nM
SRT3109			CXCR2, pIC₅₀: 8.2					99.82%
Balixafortide					CXCR4, IC₅₀: <10 nM
AZ10397767			CXCR2, IC₅₀: 1 nM
CXCR4 antagonist 7					CXCR4/CXCL12, IC₅₀: 9.3 nM
CXCR4 antagonist 10					CXCR4, IC₅₀: 7.8 nM
CXCR2 antagonist 7			CXCR2, IC₅₀: 0.044 μM
BC-1485		CXCR1
Hit 14					12G5 mAb-CXCR4, IC₅₀: 254 nM
CTCE-9908 TFA					CXCR4
CXCR2 antagonist 6			CXCR2, IC₅₀: 0.43 μM
TC14012 TFA					CXCR4, IC₅₀: 19.3 nM (antagonist site)	CXCR7, EC₅₀: 350 nM (agonist site)
Nicotinamide N-oxide (Standard)			CXCR2
CXCR2 antagonist 5			CXCR2, IC₅₀: 0.013 μM
CXCR4 modulator-1					CXCR4, EC₅₀: 100 nM
CXCR4 antagonist 5					CXCR4, IC₅₀: 8.8 nM
CXCR4 antagonist 9					CXCR4, IC₅₀: 15 nM
CXCR4 antagonist 3					CXCR4, IC₅₀: 11 nM
CXCR4 antagonist 4					CXCR4, IC₅₀: 24 nM
VUF11207 TFA						CXCR7, pKi: 8.1
TIQ-15					CXCR4, IC₅₀: 6 nM
ATI-2341					CXCR4, EC₅₀: 194 nM (in CCRF-CEM cells)
CCX662						CXCR7
CXCR4 modulator-2					CXCR4, IC₅₀: 1.25 nM
CXCR4 antagonist 8					CXCR4, IC₅₀: 57 nM
Corydalmine			CXCR2
Ac-Pro-Gly-Pro-OH			CXCR2
CXCR4 antagonist 1					CXCR4
VUF11418			CXCR2
BAM-12P						CXCR7, EC₅₀: 175 nM
HF50731					CXCR4, IC₅₀: 19.8 nM
CXCR4-IN-3					CXCR4, IC₅₀: 3.2 nM
ICT5040					CXCR4, IC₅₀: 3.8 μM
RCP168					CXCR4, IC₅₀: 5 nM
CXCR2 antagonist 4			CXCR2, IC₅₀: 0.13 μM
CXCR4 antagonist 6					CXCR4, IC₅₀: 79 nM
KRH-1636					CXCR4
VUF11207						CXCR7, pKi: 8.1

Name
Email *

	Sorry, but the email address you supplied was invalid.

CXCR

CXCR

CXCR Isoform Specific Products:

CXCR Isoform Specific Products:

CXCR Related Products (225)

Recombinant Proteins (142)

Antibodies (9)

Related Compound Screening Libraries (1)

CXCR Isoform Comparison

CXCR Related Products (225):